Kendall Mault, OD
Optometrist · Salem, MANPI 1851607014
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 130 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 17 manufacturers, the largest accounting for just 21.2% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,156, 3.3 times the $353 reported in 2019. Among optometrist clinicians in MA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 130 payments — averaging $25.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sun Pharmaceutical Industries Inc.$707
- AbbVie$674
- Tarsus Pharmaceuticals, Inc.$359
- Bausch & Lomb Americas Inc.$261
- Alcon$214
- Novartis$194
- plus $934 from 11 others
Across 2 payments — averaging $26,900 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Nidek CO., LTD.$54K
What the payments were for
- Food & beverage$3,344100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sun Pharmaceutical Industries Inc. | 19 | $707 |
| AbbVie(2 entities) | 34 | $674 |
| Tarsus Pharmaceuticals, Inc. | 11 | $359 |
| Bausch & Lomb Americas Inc. | 14 | $261 |
| Alcon | 5 | $214 |
| Novartis | 9 | $194 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 8 | $188 |
| Johnson & Johnson Vision Care, Inc. | 3 | $167 |
| Oyster Point Pharma, Inc. | 6 | $144 |
| Aerie Pharmaceuticals, Inc. | 6 | $114 |
| Dompe US, Inc. | 5 | $111 |
| Amgen | 3 | $73 |
| Shire North American Group Inc | 2 | $39 |
| Kala Pharmaceuticals, Inc. | 2 | $38 |
| Thea Pharma Inc. | 1 | $21 |
| Eyepoint US, Inc. | 1 | $20 |
| Mallinckrodt Hospital Products Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Voyager DSLT$123
- Hydrus Microstent$123
How this compares
$3,344 in reported general payments places this provider in the 90th percentile of 1,084 optometrist providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 46 | $62,909 |
| LumiganBimatoprost | 82 | $41,842 |
| XiidraLifitegrast | 12 | $13,432 |
| Travoprost | 60 | $12,057 |
| Brimonidine Tartrate | 180 | $9,936 |
| Brinzolamide | 41 | $7,966 |
| Alphagan PBrimonidine Tartrate | 13 | $7,479 |
| Cyclosporine | 14 | $7,411 |
| Timolol Maleate | 248 | $7,318 |
| TyrvayaVarenicline Tartrate | 11 | $7,256 |
| VyzultaLatanoprostene Bunod | 12 | $7,070 |
| Latanoprost | 577 | $6,958 |
| CombiganBrimonidine Tartrate/Timolol | 11 | $5,974 |
| AzoptBrinzolamide | 12 | $4,621 |
| Loteprednol Etabonate | 15 | $2,105 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Alphagan P, Combigan | $674 | $118,203152 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $261 | $20,50224 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $144 | $7,25611 claims |
| AlconAzopt | $214 | $4,62112 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $188 | $2,10515 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,084 optometrist providers in Massachusetts.
Other optometrist in Salem
- Donald KorbBoston$373K
- Jaclyn GarlichBoston$162K
- Jessica CrookerScituate$99K
- Micaela CrowleyWestminster$88K
- Kristen BrownBoston$87K
- Timothy BossieBoston$75K
- Sabrina GaanMedfield$66K
- Blair O'ReillyDedham$43K
- John MagalhaesN Dartmouth$40K
- Anita GulmiriBrookline$28K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.